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Abstract
Background: We analyzed specific effects of an add-on therapy with pioglitazone compared to metformin and
their combination in patients with basal insulin treatment on biomarkers of CV risk.
Methods: In this double-blind, randomized, multicentre, active comparator controlled trial, 121 patients with type 2
diabetes were enrolled. Inclusions: treatment with basal insulin, HbA1C 6.5% - 8.5%, age 30 - 75 years. After glargine
therapy over 2 weeks for titration towards FBG ≤ 7.8 mmol/L, patients received either (A) bid 850 mg metformin (n
= 42), (B) bid 15 mg pioglitazone (n = 40), or (C) 30 mg pioglitazone plus 1.7 g metformin (n = 39) over 6 months.
Matrix Metal Proteinase 9 (MMP-9) was primary objective, together with biomarkers of CV risk.
Results: Pioglitazone (B) reduced MMP-9 versus baseline by 54.1 + 187.1 ng/mL, with metformin (A) it was
increased by 49.6 + 336.2 ng/mL (p = 0.0345; B vs. A), and with the combination of both (C) it was decreased by
67.8 + 231.4 ng/mL (A vs. C: p = 0.0416; B vs. C: p = 0.8695). After logarithmic transformation due to high variances
the exploratory results showed significance for A vs. B (p = 0.0043) and for A vs. C (p = 0.0289).
Insulin dosage was reduced by 7.3 units in group B (p < 0.0001), by 6.0 units in C (p = 0.0004), but was increased
by 2.5 units (p = 0.1539) in A at follow up. Reduction in hs-CRP was significant within treatment groups for B (p =
0.0098) and C (p < 0.0001), and between the groups for A vs. C (p = 0.0124). All three single regimens reduced
PAI-1. Adiponectin was significantly elevated in B and C (p < 0.0001) and between-groups. HbA1C was only
significantly decreased in the combination group. No significant effects were observed for NFkB and PGFa.
peripheral edema were seen in 11.9% vs. 40.0% vs. 20.5%, and weight change was -0.7 kg vs. +4.3 kg vs. +2.7 kg (A
vs. B vs. C).
Conclusions: Addition of pioglitazone but not of metformin reduces MMP-9, hs-CRP and increased insulin
sensitivity and adiponectin in this study. The combination of both had no additional effect on inflammation.
Pioglitazone is suggested to be a rational add-on therapy to basal insulin in patients with high CV risk.
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Along with control of hyperglycemia, treatment of
patients with type 2 diabetes is aimed to reduce the ele-
vated risk of cardiovascular disease (CVD) by correcting
dyslipidemia, hypertension, low grade inflammation, and
abnormalities in blood coagulation. International guide-
lines recommend the combination of metformin with
basal insulin if monotherapy with metformin does not
reach the target [1]. Combinations of insulin with piogli-
tazone and with metformin plus pioglitazone are consid-
ered as less validated therapies. So far efficacy and safety
of pioglitazone in patients with stable treatment of basal
insulin have not been assessed in comparative trials with
metformin or metformin plus pioglitazone. Nevertheless,
there are some reports on the effect of an add-on ther-
apy with pioglitazone in patients with poorly controlled
type 2 diabetes under intensified insulin therapy demon-
strating that addition of pioglitazone significantly
improved not only glycemic control but also had a posi-
tive effect on some major CV risk factors. Data from
outcome studies suggest that metformin [2] and piogli-
tazone [3] can reduce CV events and progression of
atherosclerosis. Insulin treatment, however, had no sig-
nificant effect on cardiovascular outcome in the UKPDS
[2].
Due to the absence of outcome data for a combination
treatment of OAD with insulin, evaluation of CV risk
markers can be used as surrogate parameters. So far a
benefit/risk ratio for the comparator drugs as add-on
therapy to insulin was only evaluated in patients with
HbA1C >8 %[ 4 ] .W i t ha nH b A 1C < 7% recommended
by the ADA [5] and international guidelines, combina-
tion treatment under routine daily conditions is already
considered for HbA1C between 7 and 8%. For this com-
mon clinical scenario determination of biomarkers of
cardiovascular risk may help to evaluate possible bene-
fits of combination treatment in high-risk patients.
Besides hs-CRP [6,7], the matrix metalloproteinase 9
(MMP-9) is a known marker of inflammation produced
by macrophages which contributes to vascular remodel-
ling and transformation of stable to unstable plaques.
Although MMP-9 seems to reflect an overall burden of
vascular disease in type 2 diabetes patients [8-13] it is
still controversially discussed to use it as a reliable sur-
rogate marker of CV risk to date [14-16]. Hence, the
primary outcome measure of the underlying double-
blind, multi-centre, randomized, parallel three-arm trial
was to investigate the effect of pioglitazone in compari-
son to metformin and the combination of both on
MMP-9 together with a spectrum of established risk fac-
tors and biomarkers of inflammation during a 6-month
therapy in type 2 diabetes patients pre-treated with insu-
lin in order to use the generated data for evaluation of
possible beneficial effects of comparator drugs as add-on
treatment on cardiovascular risk. Clinical results and
adverse events/side effects were secondary objectives.
Methods
Study Design and Patients
Type 2 diabetes patients treated with insulin (i.e., long
acting basal insulin analogs, NPH insulin or combination
insulin) in 1-2 daily doses for at least 3 months with or
without oral antidiabetic drugs (OAD) except thiazolidi-
nediones (TZD) prior to study entry were considered at
an age between 30 and 75 years, with a BMI of ≥ 25 kg/
m
2, and if the baseline HbA1C was between 6.5 and 8.5%.
Major exclusion criteria were uncontrolled hypertension,
cardiovascular events within the previous year, and well
established contraindications for metformin or pioglita-
zone regimens. An overview of the complete study design
is presented in Figure 1. A list of participating sides is
added in appendix (additional file 1)
The study was approved by the Saxonian Ethics com-
mittee. The Patients gave informed consent to take part
in the study.
Medical history and physical examination
Clinical evaluations and safety assessments including
vital signs were done at screening, at randomisation,
during study therapy, and at the last follow-up visit.
Blood efficacy parameters were analysed in two central
laboratories, blood safety parameters in local units. Body
weight, insulin dosage, edemas, hypoglycemic episodes,
and other possible side effects were recorded at each
visit.
During an initial run-in phase of at least 2 weeks pre-
existing insulin glargine therapy was titrated to an FBG
of ≤ 7.8 mmol/L and other oral antidiabetics were
stopped. If another insulin was used as previous therapy
further treatment used insulin glargine. Patients were
advised to measure FBG daily in order to adjust the
insulin glargine dosage during the 6-month study treat-
ment phase to a titration target of FBG between ≥ 4.5
and ≤ 6.7 mmol/L based on the investigator’s discretion.
Laboratory methods
Efficacy laboratory analyses were done according to each
manufacturer’si n s t r u c t i o n si n2c e n t r a lu n i t sa n dp r o -
vided MMP-9 as primary parameter (ELISA of R&D sys-
tems, Wiesbaden/Germany). Secondary variables were:
renal function (urinary albumin and creatinine excre-
tion, crea./alb.-ratio, GFR), lipid profile (LDL/HDL/tri-
glycerides: enzymatic/GPO-PAP, Selectra of Greiner
Diagnostics, Bahlingen/Germany), metabolic markers
(HbA1C,g l u c o s e ,i n s u l i n ,H O M A - S ,a n da d i p o n e c t i n
which was measured by manual ELISA, Anthos, IBL,
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CRP: turbidimetry with Falcor 350 by Menarini, Neuss/
Germany; PAI-1 with ELISA reader of American diag-
nostics, Pfungstadt/Germany), oxidative stress (urinary
8iso PGF2a by manual ELISA with Anthos of IBL, Ham-
burg/Germany), and insulin dosage. Patients with hs-
CRP values >10 mg/dL were excluded from analysis due
to possible distortion by general inflammations. Safety
laboratory analyses yet included hematology, liver
enzymes, potassium, creatinine, and CK.
Statistical analysis
Efficacy analyses were done for the full analysis set
(ITT), safety issues for the all patients treated (safety)
analysis set. The primary statistical analysis was the test-
ing of the effect of pioglitazone in comparison to met-
formin and the combination of both on a possible
change of MMP-9 after a 6-month treatment compared
to baseline. Confirmatory statistics was based on 2-sided
t-tests for two independent samples calculated with the
parameter estimates of an analysis of covariance
(ANCOVA), using the primary parameter as dependent
variable, the treatment group (with two levels) and cen-
tre as fixed factors, and the baseline MMP-9 value as
covariate. Patients who terminated treatment before end
of 6 months were considered with their individual last
value under study medication (LOCF). Missing baseline
MMP-9 values were not replaced.
The primary confirmatory analysis concerned the final
statistical evaluation (second stage), was planned after
completion of the 6-month visit, and was clearly to be
distinguished from supporting secondary, exploratory
evaluations. All p-values and confidence levels of addi-
tional inferential statistics were interpreted exploratorily.
The confirmatory statistical evaluation was performed
using a two-stage group-sequential Pocock design since
Treatment with 
insulin (long-acting 
basal insulin 
analogues, NPH 
insulin, or 
combination insulin; 
with or without OAD 
therapy since ≥ 3 
months 
V1 V2 V3  V4  V5  V6 
   -14 
at least 
0  42+5  84+5  126+5  168+5 
Visit 
Time 
(days)
Initial run-in phase of at least 
2 weeks with insulin glargine 
(monotherapy) titrated to FBG 
≤ 7.8 mmol/L 
Treatment phase of 6 months
Insulin glargine (titrated acc. FBG) + Metformin (2 x 850mg daily) Group 1
Insulin glargine (titrated acc. FBG) + Pioglitazone (2 x 15mg daily) Group 2
Insulin glargine (titrated acc. FBG) + Metformin (2 x 850mg daily) 
+ Pioglitazone (2 x 15mg daily)  Group 3
V1.1
   -14 
at least 
Titrated to FBG < 6.7 and ≥ 4.5mmol/L
Figure 1 Chart of Study Design.
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lysis. Two null-hypotheses were tested starting with H11
vs. H12 (C vs. A) at a significance level of a = 0.0307 (2-
sided) for both study stages. A second test, H21 vs. H22,
(B vs. A) was to be done confirmatorily only if the first
test reached statistical significance. The third hypothesis
(H31 vs. H32; C vs. B) was analyzed analogously in the
exploratory sense only.
Results
Demographics and Baseline
A total of 121 patients on stable therapy with glargine
insulin were randomized to receive additional treat-
ment with metformin (850 mg bid; n = 42), pioglita-
zone (15 mg bid; n = 40), or the combination of both
(n = 39). 39 patients in the metformin arm (A), 37
with pioglitazone (B), and 37 for the combination (C)
were valid for intention to treat (i.e. full analysis set n
= 113). Thus, 8/121 patients (6.6%; 3 vs. 3 vs. 2) were
excluded as they failed to provide either evaluable
baseline or at least one post-baseline value for MMP-9.
74/121 patients (61.1%) were male (23 vs. 25 vs. 26)
and 47/121 patients (38.8%) were female (19 vs. 15 vs.
13), all Caucasians. Patient demographics (Table 1)
showed a balance in major baseline characteristics at
the time of randomization. The level of diabetes con-
trol with insulin glargine monotherapy during run-in
resulted in HbA1C of 7.3% for all 3 groups. Patients
had a diabetes history of >11 years and a 86% preva-
lence of hypertension. Average baseline results revealed
FBG of 8.35 (± 2.17) mmol/L, hs-CRP of 3.21 (± 2.54)
mg/L, and MMP-9 of 566.0 (± 266.2) ng/mL, repre-
senting a high-risk population for CVD despite subop-
timal therapy with insulin.
Efficacy - Biomarkers of Cardiovascular Risk
For MMP-9 and most of the risk factors the additional
use of pioglitazone was associated with more favourable
effects compared to treatment with metformin (Table
2). Pioglitazone (B) reduced MMP-9 by 54.1 + 187.1 ng/
mL whereas metformin (A) increased MMP-9 by 49.6 +
336.2 ng/mL (p = 0.0345; B vs. A). The combination of
both (C) was associated with a decrease in MMP-9 of
67.8 + 231.4 ng/mL (p = 0.0416, A vs. C and p =
0.8695, B vs. C). Logarithmic transformation for stabili-
zation of the observed high variances revealed a rise of
0.1 + 0.5 ng/mL for A and a decrease of 0.1 +0 . 5n g /
mL for both B and C. Now, exploratory p-values for the
between-group comparison using the 3-group ANCOVA
model reached significance for A vs. B (p = 0.0043) and
for A vs. C (p = 0.0289), based on the pre-defined sig-
nificance level of a = 0.0307.
Reduction of hs-CRP was significant within-group for
B (p = 0.0098) and C (p < 0.0001), and between-group
Table 1 Demographic and Baseline Data
Baseline Parameter Items Total; n = 121 Metformin n = 42 Pioglitazone n = 40 MET + PIO n = 39
Sex Male (%) 74 (61.2) 23 (54.8) 25 (62.5) 26 (66.7)
Female (%) 47 (38.8) 19 (45.2) 15 (37.5) 13 (33.3)
Age [years] Mean (SD) 63.0 (7.5) 64.2 (7.3) 61.5 (7.1) 63.3 (7.9)
Weight [kg] Mean (SD) 92.5 (17.3) 89.4 (13.8) 91.9 (16.2) 96.6 (20.9)
BMI [kg/m
2] Mean (SD) 32.2 (5.3) 31.8 (5.0) 31.7 (4.3) 33.1 (6.4)
Duration of Diabetes Type 2 in [years] Mean (SD) 11.1 (6.2) 12.3 (6.8) 9.8 (5.8) 11.0 (5.7)
Median 10.0 11.0 8.0 10.0
Range 1.0 - 31.5 3.0 - 31.5 1.0 - 28.0 1.3 - 29.0
SBP [mmHg] Mean (SD) 137.5 (14.0) 138.8 (16.1) 137.0 (10.7) 136.5 (14.9)
DBP [mmHg] Mean (SD) 78.1 (8.4) 78.5 (10.1) 77.5 (7.5) 78.2 (7.2)
FBG [mmol/L] Mean (SD) 8.35 (2.17) 8.01 (1.96) 8.83 (2.52) 8.22 (1.95)
Insulin units Mean (SD) 36.3 (20.9) 36.3 (20.1) 37.7 (22.9) 34.9 (19.9)
HbA1C [%] Mean (SD) 7.34 (0.53) 7.35 (0.53) 7.33 (0.53) 7.34 (0.54)
MMP-9 [ng/mL] Mean (SD) 566.0 (266.2) 589.7 (309.1) 530.9 (226.4) 576.5 (257.1)
hs-CRP [mg/L] Mean (SD) 4.19 (4.14) 4.77 (4.91) 3.98 (3.43) 3.76 (3.93)
hs-CRP ≤ 10 [mg/L]; Mean (SD) 3.21 (2.54) 3.17 (2.37) 3.41 (2.87) 3.05 (2.39)
Creatinine [mg/dL] Mean (SD) 0.84 (0.19) 0.81 (0.19) 0.86 (0.17) 0.86 (0.22)
Conc. BP-lower. ther. n (%) 106 (87.6) 39 (92.9) 37 (92.5) 30 (76.9)
Conc. lipid-lower. ther. n (%) 59 (48.8) 22 (52.4) 19 (47.5) 18 (46.2)
Conc. hypertension n (%) 104 (86.0) 37 (88.1) 36 (90.0) 31 (79.5)
Conc. CHD n (%) 23 (19.0) 13 (31.0) 7 (17.5) 3 (7.7)
Percentages are based on the total number of patients per group; SD: standard deviation; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic
blood pressure; FBG: fasting blood glucose; HbA1C: haemoglobin A1c; MMP-9: matrix metallo proteinase-9; conc.: concomitant; lower.: lowering; ther.: therapy;
CHD: coronary heart disease.
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reduced PAI-1 within-group but without any signifi-
cance for the between-group comparisons. No effects
were observed on the level of fibrinogen with any of the
3 regimens. The same applies for PGFa and NFkB activ-
ity. Adiponectin was significantly increased in group B
and C (p < 0.0001) without an effect for metformin
alone. This was confirmed between the groups with p <
0.0001 for A vs. B and A vs. C.
Figure 2 illustrates the different effects of the three
treatment regimens on MMP-9, insulin resistance and
inflammation, indicating a clear superiority of pioglita-
zone with respect to biomarkers of inflammation, insulin
resistance, and adiponectin.
Table 2 Course of Efficacy Parameters - Absolute Values
Secondary Efficacy
Parameter [Unit]
absolute values during the study period: baseline vs. LOCF (full analysis set, n = 113);
displayed as ‘arithmetic means ± standard deviation (medians); n patients’
A: Metformin (n = 39) B: Pioglitazone (n = 37) C: MET + PIO (n = 37)
Baseline
a LOCF Baseline
a LOCF Baseline
a LOCF
Fasting glucose
[mmol/L] (2)
7.97 ± 1.98 (8.10);
39
7.32 ± 1.90 (6.79);
39 *
8.73 ± 2.58 (8.40);
37
7.34 ± 1.58 (6.99);
37 *
8.21 ± 1.96 (7.81);
37
6.52 ± 1.48 (6.33);
37 *
Fasting insulin
[μIU/mL] (1) (2)
10.44 ± 9.50
(7.20); 39
12.43 ± 10.48
(9.20); 39 *
10.98 ± 7.71
(9.30); 37
7.00 ± 4.41 (5.30);
37 *
8.49 ± 6.94 (5.90);
35
6.10 ± 4.25 (4.60);
35 *
HbA1C (2) (3)
[%]
7.33 ± 0.53 (7.30);
39
7.23 ± 0.66 (7.10);
39
7.35 ± 0.54 (7.20);
37
7.19 ± 0.73 (7.20);
37
7.34 ± 0.55 (7.30);
37
6.85 ± 0.75 (6.70);
37 *
HOMA-S (1) (2)
[mmol*mU/L
2]
3.87 ± 3.89 (2.38);
39
4.14 ± 3.84 (2.64);
39
4.60 ± 3.93 (2.93);
37
2.39 ± 1.79 (1.85);
37 *
3.40 ± 3.73 (1.97);
35
1.80 ± 1.30 (1.22);
35 *
MMP-9
[ng/mL]
601.7 ± 317.0
(544.8); 39
651.3 ± 365.3
(543.3); 39
535.0 ± 214.9
(533.7); 37
480.9 ± 232.4
(443.2); 37
581.8 ± 260.7
(504.5); 37
514.0 ± 219.5
(474.3); 37
MMP-9 - Ln
[ng/mL] (1) (2)
6.3 ± 0.6
(6.3); 39
6.4 ± 0.5
(6.3); 39
6.2 ± 0.4
(6.3); 37
6.1 ± 0.5
(6.1); 37 *
6.3 ± 0.4
(6.2); 37
6.2 ± 0.4
6.2); 37
hs-CRP ≤ 10 (2)
[mg/L]
3.22 ± 2.43 (2.32);
33
2.99 ± 2.42 (2.00);
33
3.30 ± 2.73 (2.49);
35
2.57 ± 2.07 (1.50);
35 *
2.62 ± 1.79 (1.99);
34
1.78 ± 1.06 (1.46);
34 *
Leucocytes
[/nL] (1) (2)
7.46 ± 1.86 (7.19);
39
7.26 ± 1.83 (6.90);
39
7.01 ± 1.65 (6.90);
37
6.01 ± 1.54 (5.90);
37 *
6.94 ± 1.81 (6.63);
37
6.10 ± 1.55 (6.18);
37 *
NFkB
[RLU]
1.248 ± 0.756
(0.785); 38
1.228 ± 0.688
(0.805); 38
1.024 ± 0.630
(0.745); 36
0.992 ± 0.588
(0.705); 36
1.172 ± 0.707
(0.760); 35
1.154 ± 0.703
(0.750); 35
PAI-1
[ng/mL]
71.2 ± 23.5 (70.0);
39
61.2 ± 27.7 (54.4);
39 *
71.4 ± 25.7 (76.3);
37
62.0 ± 29.9 (59.7);
37 *
70.9 ± 27.8 (76.0);
36
53.3 ± 30.4 (54.5);
36 *
Adiponectin
[mg/L] (1) (2)
4.43 ± 2.61 (4.16);
39
4.33 ± 2.34 (4.00);
39
4.29 ± 2.69 (3.85);
37
13.20 ± 8.81
(11.49); 37 *
4.83 ± 3.08 (4.11);
37
13.42 ± 7.69
(10.94); 37 *
E-Selectin
[ng/mL] (1) (2)
47.1 ± 18.7 (45.3);
39
46.5 ± 19.9 (39.2);
39
48.2 ± 17.4 (43.4);
37
43.6 ± 16.2 (38.7);
38 *
45.7 ± 16.7 (43.8);
37
42.0 ± 16.1 (41.2);
37 *
PGFa
[ng/mmol]
164 ± 89
(147); 38
186 ± 99
(168); 38
171 ± 131
(130); 36
186 ± 114
(144); 36
140 ± 46
(133); 37
162 ± 94
(138); 37
Total cholesterol
[mmol/L]
5.02 ± 0.99
(4.90);39
4.82 ± 0.90
(4.90);39
4.80 ± 0.89
(4.56);37
4.89 ± 0.89
(4.86);37
4.71 ± 0.77
(4.68);37
4.87 ± 0.86
(4.59);37
LDL-cholesterol
[mmol/L]
3.21 ± 0.78 (3.11);
38
3.08 ± 0.78 (3.12);
38
3.08 ± 0.72 (2.93);
37
3.10 ± 0.74 (3.01);
37
3.05 ± 0.62 (3.09);
37
3.11 ± 0.68 (3.07);
37
HDL-cholesterol
[mmol/L] (2) (3)
1.24 ± 0.27 (1.30);
38
1.29 ± 0.26 (1.28);
38
1.19 ± 0.39 (1.16);
37
1.29 ± 0.42 (1.17);
37 *
1.19 ± 0.29 (1.18);
37
1.41 ± 0.36 (1.42);
37 *
Triglycerides
[mmol/L]
2.03 ± 2.63 (1.54);
39
1.76 ± 0.70 (1.66);
39
1.76 ± 0.86 (1.50);
37
1.70 ± 1.04 (1.35);
37
1.72 ± 0.80 (1.71);
37
1.54 ± 0.63 (1.52);
37 *
Crea./Albu. Ratio
[mmol/mg]
1.14 ± 0.76 (1.18);
33
1.72 ± 3.12 (0.97);
33
3.47 ± 14.55
(0.88); 33
1.19 ± 1.00 (0.93);
33 *
1.89 ± 3.14 (0.80);
35
1.54 ± 1.61 (0.96);
35
GFR
[ml/min]
114.2 ± 34.2
(104.5); 39
115.8 ± 38.9
(108.7); 39
116.9 ± 33.7
(105.0); 37
115.3 ± 36.6
(106.7); 37
118.7 ± 47.3
(106.0); 37
117.2 ± 47.9
(106.0); 37
Mean insulin dos.; [units]
(1) (2)
35.2 ± 17.1 (32.0);
38
37.7 ± 19.6 (35.2);
38
34.5 ± 16.9 (33.0);
35
27.2 ± 14.6 (25.9);
35
35.4 ± 20.3 (32.4);
37
29.4 ± 20.9 (24.2);
37
MET = Metformin; PIO = Pioglitazone; Ln = logarithmic transformation; LOCF = last observation carried forward
a): baseline = values of V2.2 (randomization) or screening as applicable; dos. = dosage
* = p < 0.0307 for within group comparisons
(1) = p < 0.0307 for MET vs. PIO; (2) = p < 0.0307 for MET vs. MET+PIO; (3) = p < 0.0307 for PIO vs. MET+PIO.
Hanefeld et al. Cardiovascular Diabetology 2011, 10:65
http://www.cardiab.com/content/10/1/65
Page 5 of 9Efficacy - Metabolic and Hormonal Parameters
Metformin or pioglitazone had only minor effects on
HbA1C (A: -0.11%, B: -0.15%) whereas the combination
of both reached significance within-group (C: -0.49%, p
< 0.0001), all versus baseline. The number of patients
with a result for HbA1C of < 7% at randomization was
11/42 (26.2%; A) vs. 12/40 (30.0%; B) vs. 9/39 (23.1%;
C). The pertinent result for the individual last visit was
17/42 (40.5%) vs. 13/40 (32.5%) vs. 25/39 (64.1%) of
patients.
Fasting insulin and glucose were reduced in all 3 arms,
whereas HOMA-S was improved only for B (p < 0.0001)
and C (p < 0.0001). Thus, the between-group effect on
HOMA-S was significant for A vs. B (p = 0.0001) and A
vs. C (p < 0.0001). Eventually, mean insulin dosage was
reduced by 7.3 units in group B (p < 0.0001) and by 6.0
units in C (p = 0.0004), but was increased in the metfor-
min arm by 2.5 units (p = 0.1539). Thus, the between-
group comparison on insulin dosage was significant for
A vs. B (p < 0.0001) and for A vs. C (p = 0.0005). A
minor but relevant increase in HDL-cholesterol was
observed for both arms with pioglitazone (B: p = 0.0015;
C: p < 0.0001). Between-group comparisons revealed a
stronger increase in HDL for C vs. A (p = 0.0004) and
C vs. B (p = 0.0162). A marked reduction of triglycer-
ides was only observed for the combination arm (p =
0.0229). No such effects occurred with LDL-cholesterol.
Excretion of 8isoPGF2a, an established indicator of oxi-
dative stress, was not affected by addition of the study
drugs. Moreover, only pioglitazone improved creatinin/
albumine ratio in urine during the study period. How-
ever, GFR remained unchanged in all groups.
Safety
Adverse events were documented in 99/121 patients
(81.8%; 32 vs. 35 vs. 32, A vs. B vs. C) showing 383 (138
vs. 136 vs. 109) single events. Most frequently reported
were nasopharyngitis in 32/121 (26.4%; 10 vs. 10 vs. 12),
peripheral oedema in 29/121 (24.0%; 5 vs. 16 vs. 8),
hypoglycemia in 28/121 (23.1%; 9 vs. 8 vs. 11), weight
increase in 21/121 (17.4%; 3 vs. 11 vs. 7), and fatigue in
12/121 (9.9%; 5 vs. 1 vs. 6) patients. The calculated
mean weight change was -0.7 kg in A, 4.3 kg in B, and
2.7 kg in C. Events assessed as related to study drug
administration were mainly hypoglycemia in 26/121
( 2 1 . 5 % ;9v s .7v s .1 0 ) ,p e r i p h e r a lo e d e m ai n2 6 / 1 2 1
(21.5%; 5 vs.14 vs. 7), weight increase in 21/121 (17.4%;
3 vs. 11 vs. 7), fatigue in 8/121 (6.7%; 4 vs. 1 vs. 3), and
vertigo in 7/121 patients (5.8%; 4 vs.1 vs. 2). The better
control of HbA1C in the combination group C was not
associated with an increased risk of hypoglycemia. Pre-
mature termination due to an adverse event was seen in
9/121 patients (7.4%; 1 vs. 5 vs. 3) reporting 13 (4 vs.
5 vs. 4) events.
Discussion
This prospective, randomized, controlled trial in patients
with long-term type 2 diabetes on high cardiovascular
risk under the conditions of stable insulin treatment
reveals significant improvements with increased levels
for biomarkers of lowgrade inflammation, insulin resis-
tance, and associated CV risk factors, regarding the add-
on therapy with pioglitazone and the combination of
pioglitazone with metformin. As shown in previous stu-
dies [17-19] individual therapies have specific effects on
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Figure 2 MMP-9 and Secondary Efficacy: Mean Difference to Baseline after 6 months.
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from good glycemic control.
We observed a clinically relevant reduction of MMP-9
activity only with pioglitazone and with the combination
of pioglitazone plus metformin. Since change in FBG
and HbA1C at follow-up was in the same range for add-
on treatment with pioglitazone and metformin resp.
these effects of the PPARg agonist on MMP-9 may
represent a direct effect rather than a consequence of
minor improvement in glucose control. This finding is
in accordance with previously published studies on com-
bination therapy with insulin [17,18,20]. Furthermore,
pioglitazone but not metformin reduced hs-CRP and
increased adiponectin and the combination of both had
no better effect on these emerging risk factors. Fibrino-
lysis activity measured with PAI-1, however, was
improved for all three regimens without any differences
between the groups. As expected, pioglitazone clearly
reduced insulin resistance calculated by HOMA whereas
metformin had no effect on insulin resistance in these
patients treated with glargine insulin. Of notice, insulin
dosage was reduced in both arms with pioglitazone by
7 and 6 units, respectively (p < 0.0001), whereas an
enhancement of insulin consumption was observed for
metformin to reach the target for FBG.
The results suggest that the observed effects of piogli-
tazone on inflammational biomarkers may be direct
consequences of PPARg activation. This hypothesis is
supported by previously published results of a rando-
mized controlled trial with non-diabetic patients suffer-
ing from cardiovascular diseases and elevated hs-CRP,
where a significant beneficial effect of pioglitazone on
hs-CRP, MMP-9 and PAI-1 could be demonstrated [21].
Oxydative stress is considered as major cause of diabetic
complications [22]. Under the conditions of the present
study with suboptimal diabetes control by stable insulin
glargine treatment and the individual add-on therapy
with OAD had no effect on 8iso PGF2a excretion. As
shown by Monnier et al. [23] insulin treatment is able
to normalize 8iso PGF2a excretion. The specific add-on
therapy had only minor effects on lipids. Only HDL-C
was significantly increased for the OAD combination vs.
metformin alone and for within group comparisons.
Accordingly, triglycerides were clearly lower at LOCF
for the combination compared to metformin. Beneficial
effects of add-on therapy with pioglitazone to intensive
insulin therapy on dyslipidemia were reported for
patients with HbA1C > 8% at baseline [24].
By extrapolation, our patients had a median diabetes
duration of 11 years and a high rate of CV comorbid-
ities treated with a polypharmacy. HbA1C at baseline
was 7.34% with stable insulin glargine treatment but was
associated with an elevated level of non-traditional CV
risk factors such as MMP-9 and hs-CRP. Of notice,
there is more and more evidence that MMP-9 serves as
indicative for the presence of unstable plaques and acti-
vated macrophages [6,25,26]. Hence, our patients repre-
sent a high-risk group for CVD, despite suboptimum
insulin treatment of type 2 diabetes and medical therapy
of associated comorbidities.
As shown in the Jupiter study a reduction of hs-CRP
by rosuvastatin resulted in a significant decrease of CV
morbidity and mortality [27]. In the PERISCOPE study
treatment with pioglitazone resulted in a non-progres-
sion of coronary plaques directly measured with quanti-
tative angiography [3,28]. Thus, it is likely that by
addition of the PPARg agonist pioglitazone we may
close a gap in protection of patients on high risk for
CVD caused by increased inflammatory activity which is
not controlled with insulin treatment alone.
Regarding the clinical results we are able to confirm a
previously reported sparing effect on insulin dose which
was not possible with metformin. A slightly lower base-
line FPG in this group did not have a relevant clinical
influence. With the triple treatment of insulin, pioglita-
zone, and metformin a significantly better control of
HbA1C could be observed but no relevant differences
were seen between the two dual combination groups
with respect to CV risk factors. Better control of HbA1C
< 7% with the combination was not associated with an
increased rate of hypoglycemic events. In accordance to
previous studies [29,30], a slight improvement of albu-
minuria was observed only for the add-on therapy with
pioglitazone. No effect, however, was observed on GFR
in all groups. In accordance to previously published stu-
dies with an add-on therapy of pioglitazone to insulin
[ 3 , 4 ]w eo b s e r v e dp e r i p h e r a le d e m a si n4 0 %o ft h e
patients treated with pioglitazone add-on therapy, as
well as weight gain in 27.5%. However no serious
adverse events were observed. Specifically no adverse
effects on the left ventricular function occurred support-
ing the results of a recent tissue doppler imaging study
investigating pioglitazone in type 2 diabetes patients
with evidence of a left ventricular diastolic dysfunction
[31].
Conclusions
In patients with long term type 2 diabetes and subopti-
mal stable insulin treatment, the addition of pioglitazone
but not metformin reduced the level of inflammatory
biomarkers such as MMP-9 and hs-CRP and increased
insulin sensitivity and adiponectin. The combination of
pioglitazone with metformin resulted in better HbA1C
and lipid control without added effect on inflammation,
fibrinolysis, and renal function. No serious side effects
were observed in any regimen but pioglitazone treat-
ment was associated with more edema and weight
gain as expected. Controlled clinical trials measuring
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benefit of individual add-on treatment with oral antidia-
betic drugs to basal insulin, a question which is of high
clinical relevance.
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